Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gregory D. Gorgas
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Beta
- -0.07
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -19.75
Financials
Net Income
$-2.43MEBITDA
$-2.42MFree Cash Flow
$-5.03MEPS (diluted)
$-8.01Shares Outstanding (diluted)
301.3K+468.0%Operating Expenses
$2.50MCash & Debt
$4.20MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-12.88M | $-49.23 |
| 2024 | $0.00 | $-9.83M | $-9.15 |
| 2023 | $0.00 | $-9.29M | $-9.42 |
| 2022 | $0.00 | $-10.08M | $-10.47 |
| 2021 | $0.00 | $-7.44M | $-17.91 |
| 2020 | $0.00 | $-4.66M | $-56.48 |
| 2019 | $0.00 | $-2.17M | $-45.00 |
| 2018 | $0.00 | $-2.34M | $-82.55 |
| 2017 | $0.00 | $-234.9K | $-9.69 |
| 2016 | $0.00 | $-29.7K | $-1.41 |
| 2015 | $0.00 | $-15.2K | $-0.72 |
| 2014 | $0.00 | $-15.3K | $-1.80 |
Valuation
ARTLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-6.98%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·40d ago·Neutral
Artelo Biosciences Announces Reverse Stock Split Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026 Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026
View source ↗ - Newsglobenewswire.com·47d ago·Positive
…apan for Patent Claims for the Intended Commercial Formulation of ART27.13 SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Gran…
View source ↗ - Newsglobenewswire.com·50d ago·Neutral
…of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a U.S. patent application covering…
View source ↗
Earnings
Tue, Nov 17(in 6 weeks)
Consensus estimate $-7.02 per share
Typical surprise -216.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-8.01 vs $-6.48miss
- Thu, May 14$-4.00 vs $-0.78miss
- Tue, Feb 24$-6.66 vs $-4.71miss
- Wed, Nov 12$-11.91 vs $-2.46miss
- Tue, Aug 12$-16.83 vs $-12.57miss
- Tue, May 13$-12.96 vs $-2.40miss
Estimates and results for ARTL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARTL officers and directors.
No open-market trades in the recent filings. All 97 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ARTL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.